A First-of-Its-Kind, ctDNA-Guided Treatment Switch

The approval is based on the SERENA-6 phase III trial, the first registrational study to use circulating tumor DNA (ctDNA) to detect emerging ESR1 mutations and trigger an early switch in endocrine therapy. Patients on an aromatase inhibitor (AI) plus a CDK4/6 inhibitor underwent routine blood-based ctDNA monitoring every 2 to 3 months. When an ESR1 mutation appeared—without radiographic progression—endocrine therapy was switched to camizestrant while continuing the same CDK4/6 inhibitor.

This approach reflects a broader trend toward molecularly adaptive treatment, where therapy changes are driven by real-time tumor evolution rather than waiting for overt progression.

Key SERENA-6 Findings

In the planned interim analysis:

• Risk of progression or death reduced by 56% with ETCAMAH + CDK4/6 inhibitor versus AI + CDK4/6 inhibitor (hazard ratio [HR], 0.44; 95% CI, 0.31-0.60; P<.00001)
• Median progression-free survival: 16.0 months versus 9.2 months
• Second disease progression: 25.7 versus 19.1 months (HR, 0.63; P=.00373)
• Overall survival: immature, but trending in favor of the ETCAMAH combination
• Safety: consistent with known profiles of camizestrant and CDK4/6 inhibitors; no new safety signals

These results, presented at the 2025 ASCO Annual Meeting and published in the New England Journal of Medicine, support the idea that intervening at the molecular onset of endocrine resistance can meaningfully delay disease progression.

Why ESR1 Mutations Matter

ESR1 mutations are a well-established driver of resistance to aromatase inhibitors. They emerge during treatment and become more common as disease advances. Approximately 30% of patients with endocrine‑sensitive HR-positive metastatic breast cancer develop ESR1 mutations during first-line therapy—often before imaging shows progression.

Once resistance develops, treatment options narrow and outcomes worsen. Only about one-third of patients with metastatic HR-positive disease are expected to live beyond 5 years.

The ETCAMAH approval introduces a new window for therapeutic intervention, enabling clinicians to act at the moment ESR1 mutations appear.

Companion Diagnostic Approved in Parallel

The FDA also cleared a companion ctDNA test to detect emerging ESR1 mutations. This diagnostic is central to the SERENA-6 strategy and is now authorized for use in guiding treatment decisions in HR-positive, HER2-negative advanced breast cancer.

A Potential Shift in First-Line Management

While camizestrant is already approved in more than 30 countries, the US decision is notable for its mutation-triggered, first-line setting—a space historically dominated by AIs paired with CDK4/6 inhibitors.

The approval positions ETCAMAH as the first therapy designed specifically to preempt endocrine resistance rather than respond to it, potentially reshaping how clinicians manage HR-positive metastatic breast cancer.

What Oncologists Are Watching Next

• Maturing overall survival data from SERENA-6
• Real-world adoption of ctDNA-guided treatment switching
• Integration with existing CDK4/6 inhibitor regimens
• Impact on sequencing of endocrine therapies in metastatic disease